%0 Journal Article %A Susan M. Sherman %A Louise E. Smith %A Julius Sim %A Richard Amlôt %A Megan Cutts %A Hannah Dasch %A G James Rubin %A Nick Sevdalis %T COVID-19 vaccination intention in the UK: Results from the ‘COVID-19 Vaccination Acceptability Study’ (CoVAccS), a nationally representative cross-sectional survey %D 2020 %R 10.1101/2020.08.13.20174045 %J medRxiv %P 2020.08.13.20174045 %X Aim To investigate factors associated with intention to be vaccinated against COVID-19.Methods Online cross-sectional survey of 1,500 UK adults, recruited from an existing online research panel. Data were collected between 14th and 17th July 2020. We used linear regression analyses to investigate associations between intention to be vaccinated for COVID-19 “when a vaccine becomes available to you” and socio-demographic factors, previous influenza vaccination, general vaccine attitudes and beliefs, attitudes and beliefs about COVID-19, and attitudes and beliefs about a COVID-19 vaccination.Results 64% of participants reported being likely to be vaccinated against COVID-19; 27% were unsure and 9% reported being unlikely to be vaccinated. Personal and clinical characteristics, previous influenza vaccination, general vaccination beliefs, and beliefs and attitudes about COVID-19 and a COVID-19 vaccination explained 77% of the variance in vaccination intention. Intention to be vaccinated was associated with more positive general COVID-19 vaccination beliefs and attitudes, weaker beliefs that the vaccination would cause side effects or be unsafe, greater perceived information sufficiency to make an informed decision about COVID-19 vaccination, greater perceived risk of COVID-19 to others but not oneself, older age, and having been vaccinated for influenza last winter (2019/20).Conclusions Despite uncertainty around the details of a COVID-19 vaccination, most participants reported intending to be vaccinated for COVID-19. Actual uptake will likely be lower. Vaccination intention reflects general vaccine beliefs and attitudes. Campaigns and messaging about a COVID-19 vaccination should emphasize the risk of COVID-19 to others and necessity for everyone to be vaccinated.Competing Interest StatementNS is the director of the London Safety and Training Solutions Ltd, which offers training in patient safety, implementation solutions and human factors to healthcare organisations. The other authors have no conflicts of interest to declare.Funding StatementData collection was funded by a Keele University Faculty of Natural Sciences Research Development award to SS, JS and NS, and a Kings Together Rapid COVID-19 award granted jointly to LS, GJR, RA, NS, SS and JS. LS, RA and GJR are supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emergency Preparedness and Response, a partnership between Public Health England, Kings College London and the University of East Anglia. NS research is supported by the National Institute for Health Research (NIHR) Applied Research Collaboration (ARC) South London at Kings College Hospital NHS Foundation Trust. NS is a member of Kings Improvement Science, which offers co-funding to the NIHR ARC South London and comprises a specialist team of improvement scientists and senior researchers based at Kings College London. Its work is funded by Kings Health Partners (Guys and St Thomas NHS Foundation Trust, Kings College Hospital NHS Foundation Trust, Kings College London and South London and Maudsley NHS Foundation Trust), Guys and St Thomas Charity and the Maudsley Charity. The views expressed are those of the authors and not necessarily those of the NIHR, the charities, Public Health England or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Keele University Research Ethics Committee (reference: PS-200129)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe link provided is a read-only link. On acceptance this will be updated to a fully accessible link to the data. https://osf.io/94856/?view_only=c85fd2666a204c67b2c41f0ded105ec2 %U https://www.medrxiv.org/content/medrxiv/early/2020/08/14/2020.08.13.20174045.full.pdf